In this episode of the Psychedelic Spotlight podcast, we feature Anthony Tennyson, CEO of Awakn Life Sciences, a biotechnology company with clinical operations developing and delivering psychedelic medicine to treat addiction.
In our conversation with Anthony, we gain insight on Awakn’s psychedelic therapy delivery activities, the company’s plans to expand across the EU, and what the addition of renowned neuroscientist, Professor David Nutt as their Chief Research Officer means to their ongoing growth initiatives.
*To learn more about the company featured in this interview and the work they’re doing, visit their website: https://awaknlifesciences.com
*Get the latest industry news around all things psychedelics by visiting our website and be sure to subscribe to our newsletter to never miss a thing.
Subscribe to our YouTube channel: https://bit.ly/3prTiCI
Visit our Website: https://psychedelicspotlight.com
Follow us on Instagram: https://instagram.com/psycspotlight
Like us on Facebook: https://facebook.com/PsychedelicSpotlight
Follow us on Twitter: https://twitter.com/PsycSpotlight
*This interview was recorded on June 30, 2021.
Have you heard about our new community?
We’re excited to announce Bonfire -
a personal growth community for people who are interested in psychedelics.
Join us for our launch event on July 18th, where we’ll share about the work we’ll be doing together to actualize our personal missions, grow, and heal together.
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.